Publications

Gossec et al. demonstrated that tofacitinib significantly reduced fatigue in patients with ankylosing spondylitis, with median times to clinically meaningful improvements of 8 and 12 weeks for initial and stable improvement events, respectively. These changes were observed as early as two weeks and were more pronounced compared to placebo.

The authors assessed the time to initial and sustained fatigue improvement using the FACIT-F scale in patients receiving tofacitinib 5 mg twice daily versus placebo. The study aimed to provide temporal benchmarks for fatigue alleviation in active ankylosing spondylitis patients.